MA42397B1 - 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b - Google Patents
4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2bInfo
- Publication number
- MA42397B1 MA42397B1 MA42397A MA42397A MA42397B1 MA 42397 B1 MA42397 B1 MA 42397B1 MA 42397 A MA42397 A MA 42397A MA 42397 A MA42397 A MA 42397A MA 42397 B1 MA42397 B1 MA 42397B1
- Authority
- MA
- Morocco
- Prior art keywords
- azaindoles
- substituted
- modulators
- receptor
- glun2b receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des 4-azaindoles substitués utilisés en tant que ligands du récepteur de nr2b. De tels composés peuvent être utilisés dans la modulation de récepteurs de nr2b ainsi que dans des compositions pharmaceutiques et des méthodes pour le traitement d'états pathologiques, de troubles et d'affections médiés par l'activité du récepteur de nr2b.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562190416P | 2015-07-09 | 2015-07-09 | |
PCT/US2016/041339 WO2017007938A1 (fr) | 2015-07-09 | 2016-07-07 | 4-azaindoles substitués et leur utilisation comme modulateurs du récepteur de glun2b |
EP16741469.7A EP3319963B1 (fr) | 2015-07-09 | 2016-07-07 | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42397B1 true MA42397B1 (fr) | 2020-02-28 |
Family
ID=56497884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42397A MA42397B1 (fr) | 2015-07-09 | 2016-07-07 | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b |
Country Status (25)
Country | Link |
---|---|
US (2) | US9963447B2 (fr) |
EP (1) | EP3319963B1 (fr) |
JP (2) | JP6964576B2 (fr) |
KR (1) | KR20180026760A (fr) |
CN (1) | CN108026094B (fr) |
AU (1) | AU2016291158B2 (fr) |
BR (1) | BR112018000468A2 (fr) |
CA (1) | CA2991765C (fr) |
CY (1) | CY1123007T1 (fr) |
DK (1) | DK3319963T3 (fr) |
EA (1) | EA033197B1 (fr) |
ES (1) | ES2781867T3 (fr) |
HK (1) | HK1255160A1 (fr) |
HR (1) | HRP20200410T1 (fr) |
HU (1) | HUE047460T2 (fr) |
IL (1) | IL256758A (fr) |
LT (1) | LT3319963T (fr) |
MA (1) | MA42397B1 (fr) |
MD (1) | MD3319963T2 (fr) |
MX (1) | MX2018000352A (fr) |
PL (1) | PL3319963T3 (fr) |
PT (1) | PT3319963T (fr) |
SI (1) | SI3319963T1 (fr) |
WO (1) | WO2017007938A1 (fr) |
ZA (1) | ZA201800827B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
EP3180329B1 (fr) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Derives de triazole comme des inhibiteurs de recepteur nr2b |
WO2017007938A1 (fr) | 2015-07-09 | 2017-01-12 | Janssen Pharmaceutica Nv | 4-azaindoles substitués et leur utilisation comme modulateurs du récepteur de glun2b |
CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
EP3774732A4 (fr) * | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
AU2020293642A1 (en) * | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
PE20220386A1 (es) * | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
JOP20210330A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" |
CN114007691A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 吡啶氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
MX2021015500A (es) * | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
WO2022127655A1 (fr) * | 2020-12-14 | 2022-06-23 | 中国科学技术大学 | Inhibiteur de l'inflammasome nlrp3 et son utilisation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL164187A0 (en) * | 2002-03-28 | 2005-12-18 | Eisai Co Ltd | 7-Azaindole derivatives and pharmaceutical compositions containing the same |
CN101018779A (zh) | 2004-02-18 | 2007-08-15 | 阿斯利康(瑞典)有限公司 | 三唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
US7807704B2 (en) * | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 |
WO2009005821A1 (fr) | 2007-07-03 | 2009-01-08 | Edward Scott Carlson | Appareil de support pour plantes grimpantes |
US20090270359A1 (en) | 2007-08-30 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Substituted pyrazole derivatives |
EP2215073A4 (fr) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | Modulation du sommeil avec des antagonistes du récepteur nr2b |
JP2011516417A (ja) | 2008-03-27 | 2011-05-26 | エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Nmdanr2b−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
MY153606A (en) | 2008-08-05 | 2015-02-27 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-one derivatives |
JP5656848B2 (ja) * | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
TWI625121B (zh) * | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
US8765784B2 (en) | 2010-06-09 | 2014-07-01 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
WO2013130855A1 (fr) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Dérivés d'indazole |
WO2014124651A1 (fr) * | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
CN105189481A (zh) * | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
PL2970265T3 (pl) * | 2013-03-15 | 2018-11-30 | Plexxikon Inc. | Heterocykliczne związki i ich zastosowania |
CN103626767A (zh) * | 2013-12-04 | 2014-03-12 | 上海药明康德新药开发有限公司 | 区域选择性的氮杂吲哚及其合成方法 |
EP3180329B1 (fr) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Derives de triazole comme des inhibiteurs de recepteur nr2b |
US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
WO2017007938A1 (fr) | 2015-07-09 | 2017-01-12 | Janssen Pharmaceutica Nv | 4-azaindoles substitués et leur utilisation comme modulateurs du récepteur de glun2b |
CN109071488B (zh) | 2016-02-10 | 2021-08-13 | 詹森药业有限公司 | 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂 |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
-
2016
- 2016-07-07 WO PCT/US2016/041339 patent/WO2017007938A1/fr active Application Filing
- 2016-07-07 ES ES16741469T patent/ES2781867T3/es active Active
- 2016-07-07 CN CN201680052507.9A patent/CN108026094B/zh active Active
- 2016-07-07 JP JP2018500737A patent/JP6964576B2/ja active Active
- 2016-07-07 EP EP16741469.7A patent/EP3319963B1/fr active Active
- 2016-07-07 SI SI201630594T patent/SI3319963T1/sl unknown
- 2016-07-07 AU AU2016291158A patent/AU2016291158B2/en active Active
- 2016-07-07 PL PL16741469T patent/PL3319963T3/pl unknown
- 2016-07-07 KR KR1020187003560A patent/KR20180026760A/ko unknown
- 2016-07-07 BR BR112018000468-5A patent/BR112018000468A2/pt not_active Application Discontinuation
- 2016-07-07 MX MX2018000352A patent/MX2018000352A/es unknown
- 2016-07-07 CA CA2991765A patent/CA2991765C/fr active Active
- 2016-07-07 DK DK16741469.7T patent/DK3319963T3/da active
- 2016-07-07 PT PT167414697T patent/PT3319963T/pt unknown
- 2016-07-07 LT LTEP16741469.7T patent/LT3319963T/lt unknown
- 2016-07-07 MD MDE20180505T patent/MD3319963T2/ro unknown
- 2016-07-07 HU HUE16741469A patent/HUE047460T2/hu unknown
- 2016-07-07 MA MA42397A patent/MA42397B1/fr unknown
- 2016-07-07 EA EA201890245A patent/EA033197B1/ru not_active IP Right Cessation
- 2016-07-08 US US15/205,632 patent/US9963447B2/en active Active
-
2018
- 2018-01-07 IL IL256758A patent/IL256758A/en unknown
- 2018-02-08 ZA ZA2018/00827A patent/ZA201800827B/en unknown
- 2018-03-20 US US15/926,440 patent/US10377753B2/en active Active
- 2018-11-08 HK HK18114277.5A patent/HK1255160A1/zh unknown
-
2020
- 2020-03-12 HR HRP20200410TT patent/HRP20200410T1/hr unknown
- 2020-03-24 CY CY20201100280T patent/CY1123007T1/el unknown
-
2021
- 2021-08-27 JP JP2021138906A patent/JP7369743B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
EA201891799A1 (ru) | Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda | |
MA39088A1 (fr) | Compositions et procédés pour moduler des récepteurs farnesoïde x | |
MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA34969B1 (fr) | Composes et compositions en tant qu inibiteurs de trk | |
MA37525B1 (fr) | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine | |
MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
MA35945B1 (fr) | Inhibiteurs de la bêta-sécrétase | |
MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
PH12014501079A1 (en) | 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions | |
JOP20210330A1 (ar) | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" | |
MX2021015506A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. | |
MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
MA39346A1 (fr) | Hétérocycles substitués liés par fusion en tant que modulateurs gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés | |
MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA39927B1 (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA39750A (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA56501A (fr) | Composés destinés au traitement de troubles neuromusculaires | |
EA202290047A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО-ПИРИДИНАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GluN2B |